Results show that oral cepharanthine plus paclitaxel (combination therapy) significantly reduced tumor volume and increased tumor growth inhibition at day 28, the final day of dosing compared to paclitaxel alone (p=0.0049) Dose range finding demonstrates that oral...
Selection of lead candidate from initial short-list of 6 DMT-analogues Lead candidate displays superior potency in two in vitro bioassays on two relevant human cell types In vitro safety and biocompatibility testing using drug-loaded medical device demonstrates...
Provisional patent filed (April 14, 2022) to support use of PD-001 plus cabazitaxel for primary, metastatic and chemotherapy-resistant prostate cancer Final study results show that oral cepharanthine (PD-001) plus cabazitaxel combination therapy significantly reduced...
Prototype medical device engineered to deliver sustained, sub-psychedelic quantities of candidate DMT-analogues In vitro, time dependent drug elution profile evaluated for three candidate molecules Biocompatibility of drug-loaded medical device demonstrates cell-based...
Committed to the ‘pipeline-in-a-pill’ approach with PD-001 for certain cancers and COVID-19 Advances cGMP manufacturing of clinical drug supply with Southwest Research Institute Receives final positive data for recently conducted prostate cancer model and...
Patent claims on synergistic application of cepharanthine, cabazitaxel and other taxane family members used in combination to treat primary, metastatic and chemotherapy-resistant prostate cancer Expands on Company’s ‘pipeline in a pill’ strategy with...
